COGT
Cogent Biosciences, Inc.
$39.97
-0.04 (-0.10%)
At close · Jul 8
Market Cap
$6.95B
Shares
170,868,004
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.97
Open$40.12
Day$38.39–40.85
52W$9.13–43.73
Avg vol 30d3.1M
Short int13.5M · 7.9% float · 5.8d
Short vol24%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+14%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+13%
trailing
YTD return
+13%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $35 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
7 of 307 funds reported for Jun 30 · net +953.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.87% of float · ▲ +16.8% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
307 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
EPS growth
−11%
Y/Y
Free cash flow
$-266.0M
Balance sheet
$89.1M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $35 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
7 of 307 funds reported for Jun 30 · net +953.8K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.87% of float · ▲ +16.8% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
307 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $40 · 89%
52-wk high $44
vs 200-day avg +23%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COGT
this stock
Cogent Biosciences, Inc.
|
$6.95B | +12.5% | — | — | 7.9% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COGT | +3.3% | +28.3% | +13.3% | +3.3% | +12.5% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +3.5% | +27.4% | +5.9% | +3.5% | +3.2% |